Mylan CEO Bresch: 'No one's more frustrated than me' about EpiPen price furor
Under pressure, Mylan plans to boost access by expanding existing programs for patients who are facing higher costs.
Under pressure, Mylan plans to boost access by expanding existing programs for patients who are facing higher costs.